Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentamicin Therapy for RDEB Nonsense Mutation Patients
NCT02698735Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
01
Overview
A Phase 2 trial of gentamicin in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by University of Southern California. Started Feb 2016; status: completed.
02
Drugs
gentamicin
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT02698735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698735.